4.5 Review

Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach

Journal

RESPIRATORY MEDICINE
Volume 107, Issue 12, Pages 1817-1821

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2013.09.013

Keywords

Asthma; COPD; Inhaled medication; pMDI's; DPI's

Funding

  1. AstraZeneca
  2. Boehringer-Ingelheim
  3. Chiesi
  4. Merck Sharp Dohme
  5. Mundipharma
  6. Novartis
  7. Takeda
  8. Almirall
  9. Teva
  10. Boehringer-Ingelheim/Pfizer
  11. GlaxoSmithKline
  12. Meda Pharma
  13. Avontec
  14. Aerocrine
  15. Nycomed
  16. Boehringer Ingelheim
  17. MEDA
  18. MSD-Chibret
  19. Pfizer
  20. GSK
  21. Menarini
  22. Menarini Industrie Farmaceutiche
  23. Merck
  24. Medapharma
  25. Napp
  26. Sandoz

Ask authors/readers for more resources

Inhaled medication is the cornerstone of the pharmacological treatment of patients with asthma and COPD. The major two classes of inhaled medication include corticosteroids (ICS) and bronchodilators. There is a wide diversity in molecules in both classes. Moreover, there is a wide variation in delivery systems. The correct use of inhalers is not granted and patients often incur in many mistakes when using pMDIs and DPIs, despite repeated instructions. A better matching between patient and device could be accomplished if the physician is aware of: (1) the patient characteristics (disease, severity, fluctuation in airflow obstruction, etc); (2) what class of medication is indicated; (3) where in the lung the medication should be delivered; and, (4) how this can be best achieved by a given device in this specific patient. We focus on the prescription of pMDIs and DPIs at the GP office or at the outpatient clinic of the hospital, and we propose an evidence based approach enabling the caregiver to make a rational choice in only a few minutes by just considering the following four simple questions: Who?, What? Where? and How? (the so-called 3W-H approach). (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available